HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Voss, G. Articles by Hunsmann, G. Search for Related Content PubMed PubMed Citation Articles by Voss, G. Articles by Hunsmann, G. Agricola Articles by Voss, G. Articles by Hunsmann, G.

Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIV_mac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130

Gerald Voss

Deutsches Primatenzentrum, Abteilung für Virologie und Immunologie, Kellnerweg 4, 3400 Göttingen, Germany

Rhesus macaques were immunized with purified virus-derived simian immunodeficiency virus of macaques (SIV_mac) 251/32H glycoprotein 130 (gp130) or primed with recombinant vaccinia virus (VV) expressing the env gene of the SIV_mac BK28 clone and boosted subsequently with virus-derived gp130. High antibody titres of at least 10⁴ against recombinant gp140 were induced with both vaccines. Analysis of the antibody specificity with a peptide ELISA revealed that different linear epitopes were recognized after administration of virus-derived gp130 compared with those after priming with VV. Antibodies to some epitopes (peptides 10 and 49), which were also found in SIV-infected animals, were induced with both vaccines, whereas antibodies to other regions were induced by only one vaccine preparation. The analysis of the helper T cell response revealed a poor immunogenicity of the virus-derived gp130, whereas priming with VV induced a considerable helper T cell activity in all three vaccinees after the second VV infection. Using synthetic peptides, several epitopes were identified. Our observations show that immunization with a virus-derived gp130 or live recombinant VV induces a considerably different antibody and helper T cell response. These differences in immunogenicity might have important implications for further vaccine development.

Present address: Harvard Medical School, New England Regional Primate Research Center, One Pine Hill Drive, Southborough, Massachussetts 01772, U.S.A.

Received 25 February 1993; accepted 6 May 1993.